Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
3.23 (1y: +57%)
Market Cap 313.87 M P/E(ttm)
Enterprise Value 372.6 M P/B
DYAX- NAS (USA)
Dyax Corporation
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$3.23
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry		 vs
history
Cash to Debt 0.366
DYAX's Cash to Debt is ranked higher than
57% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. DYAX: 0.366 )
DYAX' s 10-Year Cash to Debt Range
Min: 0.37   Max: 32.79
Current: 0.37
0.37
32.79
Equity to Asset -0.929
DYAX's Equity to Asset is ranked lower than
62% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. DYAX: -0.929 )
DYAX' s 10-Year Equity to Asset Range
Min: -0.93   Max: 0.76
Current: -0.93
-0.93
0.76
F-Score: 2
Z-Score: -13.7
M-Score: -0.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) -34.60
DYAX's Operating margin (%) is ranked higher than
61% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. DYAX: -34.60 )
DYAX' s 10-Year Operating margin (%) Range
Min: -389.6   Max: -27.6
Current: -34.6
-389.6
-27.6
Net-margin (%) -53.5
DYAX's Net-margin (%) is ranked higher than
59% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. DYAX: -53.5 )
DYAX' s 10-Year Net-margin (%) Range
Min: -393.9   Max: -44
Current: -53.5
-393.9
-44
ROA (%) -52.7
DYAX's ROA (%) is ranked lower than
53% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. DYAX: -52.7 )
DYAX' s 10-Year ROA (%) Range
Min: -96.3   Max: -10.7
Current: -52.7
-96.3
-10.7
ROC (Joel Greenblatt) (%) -1629.40
DYAX's ROC (Joel Greenblatt) (%) is ranked lower than
61% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. DYAX: -1629.40 )
DYAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4407.4   Max: -138.9
Current: -1629.4
-4407.4
-138.9
Revenue Growth (%) 15.4
DYAX's Revenue Growth (%) is ranked higher than
93% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. DYAX: 15.4 )
DYAX' s 10-Year Revenue Growth (%) Range
Min: -29.7   Max: 15.4
Current: 15.4
-29.7
15.4
EBITDA Growth (%) -29.8
DYAX's EBITDA Growth (%) is ranked lower than
58% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. DYAX: -29.8 )
DYAX' s 10-Year EBITDA Growth (%) Range
Min: -37.4   Max: 7.7
Current: -29.8
-37.4
7.7
EPS Growth (%) -24
DYAX's EPS Growth (%) is ranked lower than
56% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. DYAX: -24 )
DYAX' s 10-Year EPS Growth (%) Range
Min: -35.3   Max: 39.7
Current: -24
-35.3
39.7
» DYAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

DYAX Guru Trades in Q2 2012

Jim Simons 30,600 sh (New)
Chuck Royce 2,316,100 sh (unchged)
PRIMECAP Management Sold Out
Louis Moore Bacon 86,900 sh (-88.79%)
» More
Q3 2012

DYAX Guru Trades in Q3 2012

PRIMECAP Management 8,732,900 sh (New)
Chuck Royce 2,316,100 sh (unchged)
Jim Simons Sold Out
Louis Moore Bacon Sold Out
» More
Q4 2012

DYAX Guru Trades in Q4 2012

Jim Simons 93,800 sh (New)
PRIMECAP Management 8,732,900 sh (unchged)
Chuck Royce 1,956,300 sh (-15.53%)
» More
Q1 2013

DYAX Guru Trades in Q1 2013

Steven Cohen 100,000 sh (New)
Jim Simons 127,025 sh (+35.42%)
Chuck Royce 1,956,300 sh (unchged)
PRIMECAP Management 8,732,900 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with DYAX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2012-09-30 New Buy0.04%$2.13 - $2.75 $ 3.2330%8732900
PRIMECAP Management 2012-06-30 Sold Out 0.02%$1.48 - $2.19 $ 3.2386%0
PRIMECAP Management 2010-09-30 Add 27.83%0.01%$2.1 - $2.55 $ 3.2339%6545000
PRIMECAP Management 2010-03-31 Add 83.29%0.01%$3.22 - $4.13 $ 3.23-10%4717500
Premium More recent guru trades are included for Premium Members only!!
» Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/S 5.80
DYAX's P/S is ranked higher than
74% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. DYAX: 5.80 )
DYAX' s 10-Year P/S Range
Min: 0.61   Max: 20.59
Current: 5.8
0.61
20.59
EV-to-EBIT 18.2
DYAX's EV-to-EBIT is ranked lower than
73% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 22.58 vs. DYAX: 18.2 )
DYAX' s 10-Year EV-to-EBIT Range
Min: 13.7   Max: 87.5
Current: 18.2
13.7
87.5

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 46.1
DYAX's Price/Net Current Asset Value is ranked higher than
68% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: 45.80 vs. DYAX: 46.1 )
DYAX' s 10-Year Price/Net Current Asset Value Range
Min: 5   Max: 169.5
Current: 46.1
5
169.5
Price/Median PS Value 0.9
DYAX's Price/Median PS Value is ranked higher than
74% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. DYAX: 0.9 )
DYAX' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 2.1
Current: 0.9
0.1
2.1
Forward Rate of Return (Yacktman) -42.78
DYAX's Forward Rate of Return (Yacktman) is ranked lower than
55% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. DYAX: -42.78 )
DYAX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -88.3   Max: -15.4
Current: -42.78
-88.3
-15.4

Business Description

Dyax Corp. is incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. The company a biopharmaceutical company with two business elements: Angioedema Franchise- The principal focus of its efforts is to identify, develop and commercialize treatments for conditions identified as plasma kallikrein (bradykinin) mediated angioedema, including hereditary angioedema (HAE), ACE inhibitor-induced angioedema (ACEI-AE) and angioedema of unknown origin, or idiopathic angioedema. It developed KALBITOR (ecallantide) on its own and since February 2010, it has been selling it in the United States for the treatment of acute attacks of HAE; and Phage Display Licensing and Funded Research Program- leverage its proprietary phage display technology through Licensing and Funded Research Program, referred to as the LFRP. This program has provided the company a portfolio of product candidates being developed by licensees, which currently includes 18 product candidates in clinical development, including four products in Phase 3 trials. It is focused on identifying and developing treatments for patients who experience plasma kallikrein (bradykinin) mediated angioedema. Using phage display technology, it developed ecallantide, a compound shown in vitro to be a high affinity, high specificity inhibitor of human plasma kallikrein. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR, are subject to extensive regulation by governmental authorities in the United States and other countries.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:DY8.Germany
» More Articles for DYAX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: DYAX, IBI, FARM, TAP, DBM Mar 20 2011 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares Mar 15 2011 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares Mar 15 2011 
Dyax Corp. Reports Operating Results (10-K) Mar 02 2011 
Dyax Corp. Reports Operating Results (10-Q) Nov 02 2010 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 5,000 Shares Sep 15 2010 
Dyax Corp. (DYAX) CFO George V Migausky buys 12,000 Shares Aug 25 2010 
Weekly CFO Buys Highlight: Apollo Investment Corp., Dyax Corp., Heska Corp., Vaughan Foods Inc., Wir Jun 05 2010 
Weekly CFO Buy Highlights: F.N.B. Corp, Great Wolf Resorts Inc, Dyax Corp, Transcat Inc, Cal Dive In Jun 20 2009 
Dyax Corp. (DYAX) CFO George V Migausky buys 9,000 Shares Jun 16 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK